1-3 of 3
Xilin Chen, MDPhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preclinical Characterization of BCX9930, a Potent Oral Complement Factor D Inhibitor, Targeting Alternative Pathway-Mediated Diseases Including Paroxysmal Nocturnal Hemoglobinuria (PNH)

Xilin Chen, MDPhD, Xiaogang Cheng, PhD, Qingde Liu, PhD, Saritha Muppa, MS, Cynthia Parker, BS, Fugang Zhu, PhD, Krishnan Raman, PhD, Pravin L Kotian, PhD, Yarlagadda S. Babu, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 32.
https://doi.org/10.1182/blood-2020-133921
Published: 2020
Journal Articles

BCX9930, a Potent, Selective, Oral Factor D Inhibitor, Demonstrates Proof-of-Concept As Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Austin Kulasekararaj, MD MRCP, FRCPath, Jacques Le Roux Malherbe, MD, Andrew McDonald, Melanie Cornpropst, PharmD, PhD, Phil Collis, PhD, Matthew Davidson, PharmD, Xilin Chen, MDPhD, Kristin Tower, Diane Gesty-Palmer, MD PhD, William P. Sheridan, MBBS, Antonio Risitano
Journal: Blood
Blood (2020) 136 (Supplement 1): 14–15.
https://doi.org/10.1182/blood-2020-138838
Published: 2020
Journal Articles

BCX9930, an Oral Factor D Inhibitor, for the Potential Treatment of Alternative Pathway Mediated Diseases: Interim Results of a Phase 1 Study in Healthy Subjects

Matthew Davidson, PharmD, Amanda Mathis, PhD, Stuart Mair, MBChB, DRCOG, DCPSA, FFPM, Diane Gesty-Palmer, MD PhD, Melanie Cornpropst, PharmD, PhD, William P. Sheridan, MBBS, Xilin Chen, MDPhD, David Reynolds, BS MT, Cynthia Parker, BS, Yarlagadda S. Babu, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 15–16.
https://doi.org/10.1182/blood-2020-138475
Published: 2020